Thomas W. Grunt, MSc, PhD
Division of Oncology, Department of Medicine I, Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria
Thomas Grunt studied cell biology at the University of Salzburg and, since 1987, he has worked in the Laboratory for Applied and Experimental Cancer Cell Biology (Division of Chemotherapy) at the University of Vienna. In 1992, he was awarded an international fellowship from the renowned Erwin Schrödinger program of the Austrian Science Fund FWF, to join the Vincent T. Lombardi Cancer Research Center at Georgetown University, Washington, D.C. After his return in 1994, he became head of the Laboratory for Cell Growth and Differentiation at the Division of Oncology within MedUni Vienna’s Department of Medicine I. In 1997, he was promoted to a professor of experimental oncology and cell biology.
From 2001 to 2019 he was heading the Signaling Networks Program at MedUni Vienna, which this year became reorganized and renamed to Cell Signaling & Metabolism Networks Program. His key areas of research are breast cancer, ovarian cancer, growth factors, cancer cell metabolism, retinoids, endocrinology, neoplastic stem cells and targeted therapies. His group is focusing on understanding the molecular interactions in complex growth regulation networks of cancer cells in order to develop new approaches for anti-cancer treatment. In the years between 2007 and 2015, Thomas Grunt was also Administrative Head of the Ludwig Boltzmann Cluster Oncology (LBCO) and became Vice President of the LBCO in 2016, which has been the predecessor of the current Ludwig Boltzmann Institute for Hematology & Oncology (LBI-HO).
Thomas Grunt has received numerous awards, for example from the International Society of Differentiation (ISD), the Austrian Society for Clinical Oncology and the Austrian Society for Hematology and Oncology. He is a member of the Editorial Board of the journal ‘Current Cancer Drug Targets’ and a member of the American Association of Cancer Research (AACR), the European Association of Cancer Research (EACR), the International Society of Differentiation (ISD), the International Society of Cancer Metabolism (ISCaM) and the Union for International Cancer Control (UICC).
Terms of Appointment: Sep 2019 - Aug 2021